← Leaderboards
Nina Stachenfeld
Pennsylvania State University, The
$8,907,589
Attributed
$12,563,310
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,563,310 · 7
By mechanism
R01$11,135,507 · 4
R21$1,427,803 · 3
Top collaborators
- Lacy M. Alexander9 shared
- Jane F Reckelhoff6 shared
- Stuart A Weinzimer2 shared
Most similar at Pennsylvania State University, The
Same institution · by research overlap
- Lacy M. Alexander$6,341,929
Others in their field
Top investigators on “Estrogens”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Howard N Hodis · University Of Southern California$41,407,306
- Bert W O'Malley · Baylor College Of Medicine$33,037,840
- Susan E. Hankinson · University Of Massachusetts Amherst$30,484,553
- David Heimbrook · Leidos Biomedical Research, Inc.$29,568,910
- Norman Wolmark · Nsabp Foundation, Inc.$27,523,275
Research focus
EstrogensMediatingVasodilationPeripheralReproductiveWomanBlood VesselsCardiovascular SystemCardiovascular Disorder RiskNitric OxideEstradiolHypertensionImpairmentResponseAffectCardiovascular DiseasesChronicVascular ResistanceInfertilityRisk FactorsExperimental StudyReceptorSignal TransductionEndothelium
Grant awards (34)
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$748,418
R01 · FY2025 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$87,918
R01 · FY2025 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$744,209
R01 · FY2024 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$87,918
R01 · FY2024 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$766,761
R01 · FY2023 · HL
Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents$266,081
R21 · FY2023 · HD
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$37,168
R01 · FY2023 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$36,505
R01 · FY2023 · HL
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$784,116
R01 · FY2022 · HL
Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents$236,095
R21 · FY2022 · HD
Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis$16,667
R01 · FY2022 · HL
Mechanisms of hypertension in women with polycystic ovary syndrome$808,175
R01 · FY2021 · HL · contact PI
Mechanisms of hypertension in women with polycystic ovary syndrome$803,934
R01 · FY2020 · HL · contact PI
Mechanisms of hypertension in women with polycystic ovary syndrome$12,960
R01 · FY2020 · HL · contact PI
Mechanisms of hypertension in women with polycystic ovary syndrome$808,427
R01 · FY2019 · HL · contact PI
Mechanisms of hypertension in women with polycystic ovary syndrome$254,940
R01 · FY2019 · HL · contact PI
Mechanisms of hypertension in women with polycystic ovary syndrome$811,151
R01 · FY2018 · HL · contact PI
Phytoestrogens, insulin resistance and endothelial function$207,612
R21 · FY2012 · HL · contact PI
Phytoestrogens, insulin resistance and endothelial function$238,669
R21 · FY2011 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$555,669
R01 · FY2010 · HL · contact PI
Compromised microcirculation in women with Polycystic Ovary Syndrome$223,143
R21 · FY2010 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$35,195
R01 · FY2010 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$564,032
R01 · FY2009 · HL · contact PI
Compromised microcirculation in women with Polycystic Ovary Syndrome$256,203
R21 · FY2009 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$604,679
R01 · FY2008 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$484,843
R01 · FY2007 · HL · contact PI
Estrogen & Progesterone Effects on Orthostatic Tolerance$32,283
R01 · FY2007 · HL · contact PI
Estrogen &Progesterone Effects on Orthostatic Tolerance$336,800
R01 · FY2005 · HL
Estrogen &Progesterone Effects on Orthostatic Tolerance$313,404
R01 · FY2004 · HL
Estrogen &Progesterone Effects on Orthostatic Tolerance$291,427
R01 · FY2003 · HL
SEX HORMONES AND BODY FLUID REGULATION$274,414
R01 · FY2003 · HL
SEX HORMONES AND BODY FLUID REGULATION$272,247
R01 · FY2002 · HL
SEX HORMONES AND BODY FLUID REGULATION$270,143
R01 · FY2001 · HL
SEX HORMONES AND BODY FLUID REGULATION$291,104
R01 · FY2000 · HL